{"id":22342,"date":"2026-07-21T13:21:14","date_gmt":"2026-07-21T17:21:14","guid":{"rendered":"https:\/\/centralmsnoticias.com.br\/?p=22342"},"modified":"2026-07-21T13:21:14","modified_gmt":"2026-07-21T17:21:14","slug":"anvisa-aprova-medicamentos-pediatricos-para-lupus-e-esclerose-multipla","status":"publish","type":"post","link":"https:\/\/centralmsnoticias.com.br\/?p=22342","title":{"rendered":"Anvisa aprova medicamentos pedi\u00e1tricos para l\u00fapus e esclerose m\u00faltipla"},"content":{"rendered":"<\/p>\n<p><a class=\"\" href=\"https:\/\/agenciabrasil.ebc.com.br\/saude\/noticia\/2026-07\/anvisa-aprova-medicamentos-pediatricos-para-lupus-e-esclerose-multipla\"><br \/>\n                    <img decoding=\"async\" src=\"https:\/\/cdn.jsdelivr.net\/gh\/sergiosdlima\/assets-ebc@1.0.0\/abr\/assets\/images\/logo-agenciabrasil.svg\" alt=\"Logo Ag\u00eancia Brasil\"><br \/>\n\t\t\t\t<\/a><\/p>\n<p><strong>A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Anvisa) aprovou nesta segunda-feira (20), a amplia\u00e7\u00e3o do tratamento de l\u00fapus e esclerose m\u00faltipla para para crian\u00e7as e adolescentes por meio de medicamentos<\/strong>. A medida foi <a href=\"http:\/\/https\/\/www.in.gov.br\/web\/dou\/-\/resolucao-re-n-2.831-de-16-de-julho-de-2026-720001328\" target=\"_blank\">publicada no Di\u00e1rio Oficial da Uni\u00e3o<\/a>.<img decoding=\"async\" src=\"https:\/\/agenciabrasil.ebc.com.br\/ebc.png?id=1697164&#038;o=rss\"><img decoding=\"async\" src=\"https:\/\/agenciabrasil.ebc.com.br\/ebc.gif?id=1697164&#038;o=rss\"><\/p>\n<p>Para crian\u00e7as a partir de 5 anos de idade com l\u00fapus eritematoso sist\u00eamico (LES) ativo, o Benlysta (belimumabe) passa a ser indicado como tratamento complementar. O medicamento \u00e9 destinado a pacientes que apresentam alto grau de atividade da doen\u00e7a, e que j\u00e1 estejam em tratamento padr\u00e3o, com corticosteroides, antimal\u00e1ricos, anti-inflamat\u00f3rios n\u00e3o esteroides ou outros imunossupressores.\u00a0<\/p>\n<\/p>\n<h3>Not\u00edcias relacionadas:<\/h3>\n<ul>\n<li><a href=\"https:\/\/agenciabrasil.ebc.com.br\/saude\/noticia\/2026-07\/anvisa-aprova-novo-medicamento-para-linfoma-nao-hodgkin\">Anvisa aprova novo medicamento para linfoma n\u00e3o Hodgkin.<\/a><\/li>\n<li><a href=\"https:\/\/agenciabrasil.ebc.com.br\/saude\/noticia\/2026-07\/gripe-anvisa-aprova-nova-vacina-com-73-de-eficacia\">Gripe: Anvisa aprova nova vacina com 73% de efic\u00e1cia\u00a0.<\/a><\/li>\n<li><a href=\"https:\/\/agenciabrasil.ebc.com.br\/saude\/noticia\/2026-06\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama\">Anvisa aprova novo medicamento oral para c\u00e2ncer de mama.<\/a><\/li>\n<\/ul>\n<p><strong>A medida abrange as alternativas em caneta aplicadora\/autoinjetora, visando reduzir a necessidade de deslocamentos a centros de infus\u00e3o e o conforto dos pacientes. <\/strong>A formula\u00e7\u00e3o intravenosa do medicamento j\u00e1 estava aprovada para pacientes pedi\u00e1tricos\u00a0<\/p>\n<p>Outro medicamento que teve amplia\u00e7\u00e3o de uso em pacientes a partir de 12 anos e 40 kgs \u00e9 o Ocrevus (ocrelizumabe), destinado ao tratamento da esclerose m\u00faltipla remitente-recorrente (EMRR). O produto \u00e9 um anticorpo monoclonal recombinante, que contribui para a redu\u00e7\u00e3o da atividade inflamat\u00f3ria associada \u00e0 doen\u00e7a.\u00a0\u00a0\u00a0<\/p>\n<h2>Sobre o l\u00fapus<\/h2>\n<p>O l\u00fapus eritematoso sist\u00eamico \u00e9 uma doen\u00e7a inflamat\u00f3ria autoimune, que pode afetar m\u00faltiplos \u00f3rg\u00e3os e tecidos, como pele, articula\u00e7\u00f5es, rins e c\u00e9rebro. Em casos mais graves, se n\u00e3o tratada adequadamente, pode levar ao \u00f3bito.\u00a0Entre os principais sintomas est\u00e3o febre, rigidez muscular e incha\u00e7os, les\u00f5es na pele que surgem ou pioram quando expostas ao sol, linfonodos aumentados e queda de cabelo.<\/p>\n<p>Segundo a Sociedade Brasileira de Reumatologia, a doen\u00e7a afeta entre 150 mil e 300 mil pessoas no Brasil, principalmente mulheres entre 20 e 45 anos. O diagn\u00f3stico \u00e9 feito a partir de uma s\u00e9rie de exames m\u00e9dicos, como hemograma, bi\u00f3psia renal, exame de urina, entre outros. O tratamento \u00e9 principalmente paliativo.\u00a0<\/p>\n<h2>Sobre a esclerose m\u00faltipla<\/h2>\n<p>J\u00e1 a\u00a0esclerose m\u00faltipla \u00e9 uma doen\u00e7a inflamat\u00f3ria cr\u00f4nica e autoimune do sistema nervoso central. O sistema imunol\u00f3gico ataca a mielina que reveste e protege as fibras nervosas, prejudicando a comunica\u00e7\u00e3o entre o c\u00e9rebro e o restante do corpo.\u00a0<\/p>\n<p>Na forma remitente-recorrente, a doen\u00e7a \u00e9 caracterizada por epis\u00f3dios de novos sintomas neurol\u00f3gicos ou agravamento dos j\u00e1 existentes, seguidos por per\u00edodos de recupera\u00e7\u00e3o parcial ou completa. A manifesta\u00e7\u00e3o dos sintomas antes dos 18 anos \u00e9 considerada uma condi\u00e7\u00e3o rara e mais grave da doen\u00e7a.\u00a0<\/p>\n<p>Entre os sintomas mais comuns est\u00e3o fadiga extrema, dorm\u00eancia, formigamento, altera\u00e7\u00f5es visuais (como vis\u00e3o turva ou dupla), fraqueza muscular, desequil\u00edbrio e dificuldade de controle da bexiga. As causas envolvem predisposi\u00e7\u00e3o gen\u00e9tica e fatores ambientais que funcionam como gatilhos, como infec\u00e7\u00f5es virais, tabagismo e obesidade. O diagn\u00f3stico \u00e9 feito por um neurologista junto a exames complementares.\u00a0<\/p>\n<p><em>*Estagi\u00e1rio sob supervis\u00e3o da jornalista Mariana Tokarnia.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Anvisa) aprovou nesta segunda-feira (20), a amplia\u00e7\u00e3o do tratamento de l\u00fapus e esclerose m\u00faltipla para para crian\u00e7as e adolescentes por meio de medicamentos. A medida foi publicada no Di\u00e1rio Oficial da Uni\u00e3o. Para crian\u00e7as a partir de 5 anos de idade com l\u00fapus eritematoso sist\u00eamico (LES) ativo, o Benlysta [&hellip;]<\/p>\n","protected":false},"author":624,"featured_media":22343,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[11],"tags":[],"class_list":["post-22342","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-saude-e-bem-estar"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Anvisa aprova medicamentos pedi\u00e1tricos para l\u00fapus e esclerose m\u00faltipla - Central MS Not\u00edcias<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/centralmsnoticias.com.br\/?p=22342\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Anvisa aprova medicamentos pedi\u00e1tricos para l\u00fapus e esclerose m\u00faltipla\" \/>\n<meta property=\"og:description\" content=\"A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Anvisa) aprovou nesta segunda-feira (20), a amplia\u00e7\u00e3o do tratamento de l\u00fapus e esclerose m\u00faltipla para para crian\u00e7as e adolescentes por meio de medicamentos. A medida foi publicada no Di\u00e1rio Oficial da Uni\u00e3o. Para crian\u00e7as a partir de 5 anos de idade com l\u00fapus eritematoso sist\u00eamico (LES) ativo, o Benlysta [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/centralmsnoticias.com.br\/?p=22342\" \/>\n<meta property=\"og:site_name\" content=\"Central MS Not\u00edcias\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/portalinfocobrasil\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-21T17:21:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cdn.jsdelivr.net\/gh\/sergiosdlima\/assets-ebc@1.0.0\/abr\/assets\/images\/logo-agenciabrasil.svg\" \/>\n<meta name=\"author\" content=\"Alice Rodrigues - Agencia Brasil\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Alice Rodrigues - Agencia Brasil\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/centralmsnoticias.com.br\\\/?p=22342#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/centralmsnoticias.com.br\\\/?p=22342\"},\"author\":{\"name\":\"Alice Rodrigues - Agencia Brasil\",\"@id\":\"https:\\\/\\\/centralmsnoticias.com.br\\\/#\\\/schema\\\/person\\\/471e504390431328435af5fda4fcae2d\"},\"headline\":\"Anvisa aprova medicamentos pedi\u00e1tricos para l\u00fapus e esclerose m\u00faltipla\",\"datePublished\":\"2026-07-21T17:21:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/centralmsnoticias.com.br\\\/?p=22342\"},\"wordCount\":532,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/centralmsnoticias.com.br\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/centralmsnoticias.com.br\\\/?p=22342#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/centralmsnoticias.com.br\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/22342-anvisa-aprova-medicamentos-pediatricos-para-lupus-e-esclerose-multipla.jpg\",\"articleSection\":[\"Sa\u00fade e Bem-Estar\"],\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/centralmsnoticias.com.br\\\/?p=22342#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/centralmsnoticias.com.br\\\/?p=22342\",\"url\":\"https:\\\/\\\/centralmsnoticias.com.br\\\/?p=22342\",\"name\":\"Anvisa aprova medicamentos pedi\u00e1tricos para l\u00fapus e esclerose m\u00faltipla - Central MS Not\u00edcias\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/centralmsnoticias.com.br\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/centralmsnoticias.com.br\\\/?p=22342#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/centralmsnoticias.com.br\\\/?p=22342#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/centralmsnoticias.com.br\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/22342-anvisa-aprova-medicamentos-pediatricos-para-lupus-e-esclerose-multipla.jpg\",\"datePublished\":\"2026-07-21T17:21:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/centralmsnoticias.com.br\\\/?p=22342#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/centralmsnoticias.com.br\\\/?p=22342\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/centralmsnoticias.com.br\\\/?p=22342#primaryimage\",\"url\":\"https:\\\/\\\/centralmsnoticias.com.br\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/22342-anvisa-aprova-medicamentos-pediatricos-para-lupus-e-esclerose-multipla.jpg\",\"contentUrl\":\"https:\\\/\\\/centralmsnoticias.com.br\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/22342-anvisa-aprova-medicamentos-pediatricos-para-lupus-e-esclerose-multipla.jpg\",\"width\":1600,\"height\":800,\"caption\":\"Anvisa aprova medicamentos pedi\u00e1tricos para l\u00fapus e esclerose m\u00faltipla\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/centralmsnoticias.com.br\\\/?p=22342#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\\\/\\\/centralmsnoticias.com.br\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Anvisa aprova medicamentos pedi\u00e1tricos para l\u00fapus e esclerose m\u00faltipla\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/centralmsnoticias.com.br\\\/#website\",\"url\":\"https:\\\/\\\/centralmsnoticias.com.br\\\/\",\"name\":\"Portal Infoco Brasil\",\"description\":\"L\u00edder de audi\u00eancia.\",\"publisher\":{\"@id\":\"https:\\\/\\\/centralmsnoticias.com.br\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/centralmsnoticias.com.br\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/centralmsnoticias.com.br\\\/#organization\",\"name\":\"Portal Infoco Brasil\",\"url\":\"https:\\\/\\\/centralmsnoticias.com.br\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/centralmsnoticias.com.br\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/centralmsnoticias.com.br\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/LOGO-PNG-AZUL.png\",\"contentUrl\":\"https:\\\/\\\/centralmsnoticias.com.br\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/LOGO-PNG-AZUL.png\",\"width\":1166,\"height\":475,\"caption\":\"Portal Infoco Brasil\"},\"image\":{\"@id\":\"https:\\\/\\\/centralmsnoticias.com.br\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/portalinfocobrasil\",\"https:\\\/\\\/www.instagram.com\\\/portalinfocobrasil\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/centralmsnoticias.com.br\\\/#\\\/schema\\\/person\\\/471e504390431328435af5fda4fcae2d\",\"name\":\"Alice Rodrigues - Agencia Brasil\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bc8373639d0a6a55ba1cda7dbc6b5c1a86a68f84ea47398f202378cca7c8004e?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bc8373639d0a6a55ba1cda7dbc6b5c1a86a68f84ea47398f202378cca7c8004e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bc8373639d0a6a55ba1cda7dbc6b5c1a86a68f84ea47398f202378cca7c8004e?s=96&d=mm&r=g\",\"caption\":\"Alice Rodrigues - Agencia Brasil\"},\"url\":\"https:\\\/\\\/centralmsnoticias.com.br\\\/?author=624\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Anvisa aprova medicamentos pedi\u00e1tricos para l\u00fapus e esclerose m\u00faltipla - Central MS Not\u00edcias","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/centralmsnoticias.com.br\/?p=22342","og_locale":"pt_BR","og_type":"article","og_title":"Anvisa aprova medicamentos pedi\u00e1tricos para l\u00fapus e esclerose m\u00faltipla","og_description":"A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Anvisa) aprovou nesta segunda-feira (20), a amplia\u00e7\u00e3o do tratamento de l\u00fapus e esclerose m\u00faltipla para para crian\u00e7as e adolescentes por meio de medicamentos. A medida foi publicada no Di\u00e1rio Oficial da Uni\u00e3o. Para crian\u00e7as a partir de 5 anos de idade com l\u00fapus eritematoso sist\u00eamico (LES) ativo, o Benlysta [&hellip;]","og_url":"https:\/\/centralmsnoticias.com.br\/?p=22342","og_site_name":"Central MS Not\u00edcias","article_publisher":"https:\/\/www.facebook.com\/portalinfocobrasil","article_published_time":"2026-07-21T17:21:14+00:00","og_image":[{"url":"https:\/\/cdn.jsdelivr.net\/gh\/sergiosdlima\/assets-ebc@1.0.0\/abr\/assets\/images\/logo-agenciabrasil.svg","type":"","width":"","height":""}],"author":"Alice Rodrigues - Agencia Brasil","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Alice Rodrigues - Agencia Brasil","Est. tempo de leitura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/centralmsnoticias.com.br\/?p=22342#article","isPartOf":{"@id":"https:\/\/centralmsnoticias.com.br\/?p=22342"},"author":{"name":"Alice Rodrigues - Agencia Brasil","@id":"https:\/\/centralmsnoticias.com.br\/#\/schema\/person\/471e504390431328435af5fda4fcae2d"},"headline":"Anvisa aprova medicamentos pedi\u00e1tricos para l\u00fapus e esclerose m\u00faltipla","datePublished":"2026-07-21T17:21:14+00:00","mainEntityOfPage":{"@id":"https:\/\/centralmsnoticias.com.br\/?p=22342"},"wordCount":532,"commentCount":0,"publisher":{"@id":"https:\/\/centralmsnoticias.com.br\/#organization"},"image":{"@id":"https:\/\/centralmsnoticias.com.br\/?p=22342#primaryimage"},"thumbnailUrl":"https:\/\/centralmsnoticias.com.br\/wp-content\/uploads\/2026\/07\/22342-anvisa-aprova-medicamentos-pediatricos-para-lupus-e-esclerose-multipla.jpg","articleSection":["Sa\u00fade e Bem-Estar"],"inLanguage":"pt-BR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/centralmsnoticias.com.br\/?p=22342#respond"]}]},{"@type":"WebPage","@id":"https:\/\/centralmsnoticias.com.br\/?p=22342","url":"https:\/\/centralmsnoticias.com.br\/?p=22342","name":"Anvisa aprova medicamentos pedi\u00e1tricos para l\u00fapus e esclerose m\u00faltipla - Central MS Not\u00edcias","isPartOf":{"@id":"https:\/\/centralmsnoticias.com.br\/#website"},"primaryImageOfPage":{"@id":"https:\/\/centralmsnoticias.com.br\/?p=22342#primaryimage"},"image":{"@id":"https:\/\/centralmsnoticias.com.br\/?p=22342#primaryimage"},"thumbnailUrl":"https:\/\/centralmsnoticias.com.br\/wp-content\/uploads\/2026\/07\/22342-anvisa-aprova-medicamentos-pediatricos-para-lupus-e-esclerose-multipla.jpg","datePublished":"2026-07-21T17:21:14+00:00","breadcrumb":{"@id":"https:\/\/centralmsnoticias.com.br\/?p=22342#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/centralmsnoticias.com.br\/?p=22342"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/centralmsnoticias.com.br\/?p=22342#primaryimage","url":"https:\/\/centralmsnoticias.com.br\/wp-content\/uploads\/2026\/07\/22342-anvisa-aprova-medicamentos-pediatricos-para-lupus-e-esclerose-multipla.jpg","contentUrl":"https:\/\/centralmsnoticias.com.br\/wp-content\/uploads\/2026\/07\/22342-anvisa-aprova-medicamentos-pediatricos-para-lupus-e-esclerose-multipla.jpg","width":1600,"height":800,"caption":"Anvisa aprova medicamentos pedi\u00e1tricos para l\u00fapus e esclerose m\u00faltipla"},{"@type":"BreadcrumbList","@id":"https:\/\/centralmsnoticias.com.br\/?p=22342#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/centralmsnoticias.com.br\/"},{"@type":"ListItem","position":2,"name":"Anvisa aprova medicamentos pedi\u00e1tricos para l\u00fapus e esclerose m\u00faltipla"}]},{"@type":"WebSite","@id":"https:\/\/centralmsnoticias.com.br\/#website","url":"https:\/\/centralmsnoticias.com.br\/","name":"Portal Infoco Brasil","description":"L\u00edder de audi\u00eancia.","publisher":{"@id":"https:\/\/centralmsnoticias.com.br\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/centralmsnoticias.com.br\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/centralmsnoticias.com.br\/#organization","name":"Portal Infoco Brasil","url":"https:\/\/centralmsnoticias.com.br\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/centralmsnoticias.com.br\/#\/schema\/logo\/image\/","url":"https:\/\/centralmsnoticias.com.br\/wp-content\/uploads\/2025\/04\/LOGO-PNG-AZUL.png","contentUrl":"https:\/\/centralmsnoticias.com.br\/wp-content\/uploads\/2025\/04\/LOGO-PNG-AZUL.png","width":1166,"height":475,"caption":"Portal Infoco Brasil"},"image":{"@id":"https:\/\/centralmsnoticias.com.br\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/portalinfocobrasil","https:\/\/www.instagram.com\/portalinfocobrasil"]},{"@type":"Person","@id":"https:\/\/centralmsnoticias.com.br\/#\/schema\/person\/471e504390431328435af5fda4fcae2d","name":"Alice Rodrigues - Agencia Brasil","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/secure.gravatar.com\/avatar\/bc8373639d0a6a55ba1cda7dbc6b5c1a86a68f84ea47398f202378cca7c8004e?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/bc8373639d0a6a55ba1cda7dbc6b5c1a86a68f84ea47398f202378cca7c8004e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bc8373639d0a6a55ba1cda7dbc6b5c1a86a68f84ea47398f202378cca7c8004e?s=96&d=mm&r=g","caption":"Alice Rodrigues - Agencia Brasil"},"url":"https:\/\/centralmsnoticias.com.br\/?author=624"}]}},"_links":{"self":[{"href":"https:\/\/centralmsnoticias.com.br\/index.php?rest_route=\/wp\/v2\/posts\/22342","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/centralmsnoticias.com.br\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/centralmsnoticias.com.br\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/centralmsnoticias.com.br\/index.php?rest_route=\/wp\/v2\/users\/624"}],"replies":[{"embeddable":true,"href":"https:\/\/centralmsnoticias.com.br\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=22342"}],"version-history":[{"count":0,"href":"https:\/\/centralmsnoticias.com.br\/index.php?rest_route=\/wp\/v2\/posts\/22342\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/centralmsnoticias.com.br\/index.php?rest_route=\/wp\/v2\/media\/22343"}],"wp:attachment":[{"href":"https:\/\/centralmsnoticias.com.br\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=22342"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/centralmsnoticias.com.br\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=22342"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/centralmsnoticias.com.br\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=22342"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}